Suppressing growth and invasion of human hepatocellular carcinoma cells by celecoxib through inhibition of cyclooxygenase-2

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745–761. doi:10.1053/j.gastro.2016.11.04828043904
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. doi:10.1055/s-2007-100712210518312
   PubMed Web of Science ®Google Scholar
• Ding YF, Wu ZH, Wei YJ, Shu L, Peng YR. Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine. J Cancer Res Clin Oncol. 2017;143(5):821–834. doi:10.1007/s00432-017-2364-z28238064
   PubMed Web of Science ®Google Scholar
• Elsharkawy AM, Mann DA. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology. 2007;46(2):590–597. doi:10.1002/hep.2180217661407
   PubMed Web of Science ®Google Scholar
• Salvado MD, Alfranca A, Haeggstrom JZ, Redondo JM. Prostanoids in tumor angiogenesis: therapeutic intervention beyond COX-2. Trends Mol Med. 2012;18(4):233–243. doi:10.1016/j.molmed.2012.02.00222425675
   PubMed Web of Science ®Google Scholar
• Gao JH, Wen SL, Yang WJ, et al. Celecoxib ameliorates portal hypertension of the cirrhotic rats through the dual inhibitory effects on the intrahepatic fibrosis and angiogenesis. PLoS One. 2013;8(7):e69309. doi:10.1371/journal.pone.006930923922700
   PubMed Web of Science ®Google Scholar
• Tang SH, Gao JH, Wen SL, et al. Expression of cyclooxygenase-2 is correlated with lncRNA-COX-2 in cirrhotic mice induced by carbon tetrachloride. Mol Med Rep. 2017;15(4):1507–1512. doi:10.3892/mmr.2017.616128259935
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhu J, Gou H, Cao D, Jiang M, Hou M. Clinical significance of COX-2, Survivin and BCL-2 expression in hepatocellular carcinoma (HCC). Med oncol. 2011;28(3):796–803. doi:10.1007/s12032-010-9519-y20401641
   PubMed Web of Science ®Google Scholar
• Yang HJ, Jiang JH, Yang YT, et al. Cyclooxygenase-2 expression is associated with initiation of hepatocellular carcinoma, while prostaglandin receptor-1 expression predicts survival. World J Gastroenterol. 2016;22(39):8798–8805. doi:10.3748/wjg.v22.i39.879827818595
   PubMed Web of Science ®Google Scholar
• Schmitz KJ, Wohlschlaeger J, Lang H, et al. Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol. 2009;62(8):690–693. doi:10.1136/jcp.2009.06588819638539
   PubMed Web of Science ®Google Scholar
• Giannitrapani L, Ingrao S, Soresi M, et al. Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann N Y Acad Sci. 2009;1155:293–299. doi:10.1111/j.1749-6632.2009.03698.x19250220
   PubMed Web of Science ®Google Scholar
• Xu L, Stevens J, Hilton MB, et al. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 2014;6(242):242ra284. doi:10.1126/scitranslmed.3008455
   Web of Science ®Google Scholar
• Regulski M, Regulska K, Prukala W, Piotrowska H, Stanisz B, Murias M. COX-2 inhibitors: a novel strategy in the management of breast cancer. Drug Discov Today. 2016;21(4):598–615. doi:10.1016/j.drudis.2015.12.00326723915
   PubMed Web of Science ®Google Scholar
• Gobel C, Breitenbuecher F, Kalkavan H, et al. Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. Cell Death Dis. 2014;5:e1568. doi:10.1038/cddis.2014.53125501829
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Xiao J, Mo Q, et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature. 2015;517(7533):209–213. doi:10.1038/nature1403425470039
   PubMed Web of Science ®Google Scholar
• Gao JH, Wen SL, Tong H, et al. Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G962–G972. doi:10.1152/ajpgi.00428.201527056726
   PubMed Web of Science ®Google Scholar
• Gao JH, Wen SL, Feng S, et al. Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats. Angiogenesis. 2016;19(4):501–511. doi:10.1007/s10456-016-9522-927380212
   PubMed Web of Science ®Google Scholar
• Wen SL, Gao JH, Yang WJ, et al. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes. J Gastroenterol Hepatol. 2014;29(11):1932–1942. doi:10.1111/jgh.1264124909904
   PubMed Web of Science ®Google Scholar
• Tong H, Wei B, Chen S, et al. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget. 2017;8(29):48303–48312. doi:10.18632/oncotarget.1568428430638
   PubMedGoogle Scholar
• Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 2004;3(3):299–307.15026550
   PubMed Web of Science ®Google Scholar
• Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology. 2003;38(3):756–768. doi:10.1053/jhep.2003.5038012939602
   PubMed Web of Science ®Google Scholar
• Abiru S, Nakao K, Ichikawa T, et al. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells. Hepatology. 2002;35(5):1117–1124. doi:10.1053/jhep.2002.3267611981761
   PubMed Web of Science ®Google Scholar
• Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–117. doi:10.1146/annurev-med-090514-01383226473416
   PubMed Web of Science ®Google Scholar
• Chu TH, Chan HH, Kuo HM, et al. Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN. Oncotarget. 2014;5(6):1475–1490. doi:10.18632/oncotarget.174524721996
   PubMedGoogle Scholar
• Breinig M, Schirmacher P, Kern MA. Cyclooxygenase-2 (COX-2)–a therapeutic target in liver cancer? Curr Pharm Des. 2007;13(32):3305–3315.18045183
   PubMed Web of Science ®Google Scholar
• Campillo A, Solanas E, Morandeira MJ, et al. Angiogenesis and proliferation markers in adjacent cirrhotic tissue could predict hepatocellular carcinoma outcome after liver transplantation. Eur J Gastroenterol Hepatol. 2014;26(8):871–879. doi:10.1097/MEG.000000000000013124922356
   PubMed Web of Science ®Google Scholar
• He YF, Jin J, Wei W, et al. Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis. Can J Gastroenterol. 2010;24(7):435–440.20652159
   PubMed Web of Science ®Google Scholar
• Mazzone PJ, Sears CR, Arenberg DA, et al. Evaluating molecular biomarkers for the early detection of lung cancer: when is a biomarker ready for clinical use? An Official American Thoracic Society Policy Statement. Am J Respir Crit Care Med. 2017;196(7):e15–e29. doi:10.1164/rccm.201708-1678ST28960111
   PubMed Web of Science ®Google Scholar
• Sui W, Zhang Y, Wang Z, et al. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H(2)(2) murine hepatocarcinoma model. Oncol Rep. 2014;31(5):2252–2260. doi:10.3892/or.2014.309324647425
   PubMed Web of Science ®Google Scholar
• Kern MA, Schoneweiss MM, Sahi D, et al. Cyclooxygenase-2 inhibitors suppress the growth of human hepatocellular carcinoma implants in nude mice. Carcinogenesis. 2004;25(7):1193–1199. doi:10.1093/carcin/bgh11014963015
   PubMed Web of Science ®Google Scholar
• Cui W, Hu SX, Tang ZY, Hu KQ. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anticancer Drugs. 2008;19(9):891–897. doi:10.1097/CAD.0b013e32830ef8ca18766003
   PubMed Web of Science ®Google Scholar
• Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res. 2001;7(5):1410–1418.11350912
   PubMed Web of Science ®Google Scholar
• Chen G, Li X, Yang J, et al. Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: a meta-analysis. Arch Med Sci. 2016;12(5):1110–1117. doi:10.5114/aoms.2016.6191627695503
   PubMed Web of Science ®Google Scholar
• Yildirim Y, Ozyilkan O, Bilezikci B, Akcali Z, Haberal M. Lack of influence of cyclooxygenese-2 expression in hepatocellular carcinomas on patient survival. Asian Pac J Cancer Prev. 2008;9(2):295–298.18712978
   PubMedGoogle Scholar
• Makhdoumi P, Zarghi A, Daraei B, Karimi G. Evaluation of cytotoxicity effects of chalcone epoxide analogues as a selective COX-II inhibitor in the human liver carcinoma cell line. J Pharmacopuncture. 2017;20(3):207–212. doi:10.3831/KPI.2017.20.02430087797
   PubMedGoogle Scholar
• Li T, Zhong J, Dong X, et al. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the beta-catenin signaling pathway. Oncol Rep. 2016;35(6):3614–3622. doi:10.3892/or.2016.476427109804
   PubMed Web of Science ®Google Scholar
• Li J, Chen X, Dong X, Xu Z, Jiang H, Sun X. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells. J Gastroenterol Hepatol. 2006;21(12):1814–1820. doi:10.1111/j.1440-1746.2006.04366.x17074019
   PubMed Web of Science ®Google Scholar
• Baek JY, Hur W, Wang JS, Bae SH, Yoon SK. Selective COX-2 inhibitor, NS-398, suppresses cellular proliferation in human hepatocellular carcinoma cell lines via cell cycle arrest. World J Gastroenterol. 2007;13(8):1175–1181.17451196
   PubMed Web of Science ®Google Scholar
• Park MK, Hwang SY, Kim JO, et al. NS398 inhibits the growth of Hep3B human hepatocellular carcinoma cells via caspase-independent apoptosis. Mol Cells. 2004;17(1):45–50.15055526
   PubMed Web of Science ®Google Scholar
• Wang G, Li J, Zhang L, Huang S, Zhao X, Zhao X. Celecoxib induced apoptosis against different breast cancer cell lines by down-regulated NF-kappaB pathway. Biochem Biophys Res Commun. 2017;490(3):969–976. doi:10.1016/j.bbrc.2017.06.14828666869
   PubMed Web of Science ®Google Scholar
• Kang KB, Zhu C, Yong SK, Gao Q, Wong MC. Enhanced sensitivity of celecoxib in human glioblastoma cells: induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. Mol Cancer. 2009;8:66. doi:10.1186/1476-4598-8-6619706164
   PubMed Web of Science ®Google Scholar
• Fransvea E, Angelotti U, Antonaci S, Giannelli G. Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology. 2008;47(5):1557–1566. doi:10.1002/hep.2220118318443
   PubMed Web of Science ®Google Scholar
• Zhou L, Wang DS, Li QJ, Sun W, Zhang Y, Dou KF. The down-regulation of Notch1 inhibits the invasion and migration of hepatocellular carcinoma cells by inactivating the cyclooxygenase-2/Snail/E-cadherin pathway in vitro. Dig Dis Sci. 2013;58(4):1016–1025. doi:10.1007/s10620-012-2434-723053901
   PubMed Web of Science ®Google Scholar
• Tashiro E, Henmi S, Odake H, Ino S, Imoto M. Involvement of the MEK/ERK pathway in EGF-induced E-cadherin down-regulation. Biochem Biophys Res Commun. 2016;477(4):801–806. doi:10.1016/j.bbrc.2016.06.13827369075
   PubMed Web of Science ®Google Scholar
• Fung TM, Ng KY, Tong M, et al. Neuropilin-2 promotes tumourigenicity and metastasis in oesophageal squamous cell carcinoma through ERK-MAPK-ETV4-MMP-E-cadherin deregulation. J Pathol. 2016;239(3):309–319. doi:10.1002/path.472827063000
   PubMed Web of Science ®Google Scholar
• Barber AG, Castillo-Martin M, Bonal DM, et al. PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. Cancer Med. 2015;4(8):1258–1271. doi:10.1002/cam4.46326033689
   PubMed Web of Science ®Google Scholar
• Lau MT, Leung PC. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett. 2012;326(2):191–198. doi:10.1016/j.canlet.2012.08.01622922215
   PubMed Web of Science ®Google Scholar
• Adlung L, Kar S, Wagner MC, et al. Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation. Mol Syst Biol. 2017;13(1):904. doi:10.15252/msb.2016725828123004
   PubMed Web of Science ®Google Scholar
• Sze KM, Wong KL, Chu GK, Lee JM, Yau TO, Ng IO. Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology. 2011;53(5):1558–1569. doi:10.1002/hep.2423221520171
   PubMed Web of Science ®Google Scholar
• Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell. 2010;38(1):114–127. doi:10.1016/j.molcel.2010.02.02020385094
   PubMed Web of Science ®Google Scholar
• Mayer IA, Arteaga CL. The PI3K/AKT Pathway as a Target for Cancer Treatment. Annu Rev Med. 2016;67:11–28. doi:10.1146/annurev-med-062913-05134326473415
   PubMed Web of Science ®Google Scholar
• Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014;13(12):928–942. doi:10.1038/nrd428125435214
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Sullivan RJ, Hwu WJ, et al. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. JCI Insight. 2018;3(4). doi:10.1172/jci.insight.92352
   PubMed Web of Science ®Google Scholar
• Saura C, Roda D, Rosello S, et al. A first-in-human phase i study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov. 2017;7(1):102–113. doi:10.1158/2159-8290.CD-16-051227872130
   PubMed Web of Science ®Google Scholar
• Gao JH, Wang CH, Tong H, Wen SL, Huang ZY, Tang CW. Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer. Sci Rep. 2015;5:16382. doi:10.1038/srep1638226567773
   PubMed Web of Science ®Google Scholar